18 May 2025
UnitedHealth Group (UNH) – Oversold & Attracting Insider Confidence
UNH has recently drawn attention after its stock price dropped over 50% since mid-April 2025. Putting aside the fundamental and media noise, the technical analysis shows that the stock is heavily oversold.
Last Friday, the stock rebounded over 6%, possibly driven by a strong show of confidence from insiders. Newly reinstated CEO Stephen Hemsley purchased approximately $25 million worth of UNH shares (86,700 shares at an average of $288.18). CFO John Rex also acquired $5 million, with directors Timothy Flynn and Kristen Gil making significant purchases as well.
From a price action standpoint, the current level appears attractive for a Dollar-Cost Averaging (DCA) approach. However, I'm personally eyeing a potential deeper discount entry zone between $200–$220, which would offer an even more compelling long-term risk-reward setup.
Strategy: Start small with DCA at current levels, but be patient for deeper dips for larger entries.
UnitedHealth Group (UNH) – Oversold & Attracting Insider Confidence
UNH has recently drawn attention after its stock price dropped over 50% since mid-April 2025. Putting aside the fundamental and media noise, the technical analysis shows that the stock is heavily oversold.
Last Friday, the stock rebounded over 6%, possibly driven by a strong show of confidence from insiders. Newly reinstated CEO Stephen Hemsley purchased approximately $25 million worth of UNH shares (86,700 shares at an average of $288.18). CFO John Rex also acquired $5 million, with directors Timothy Flynn and Kristen Gil making significant purchases as well.
From a price action standpoint, the current level appears attractive for a Dollar-Cost Averaging (DCA) approach. However, I'm personally eyeing a potential deeper discount entry zone between $200–$220, which would offer an even more compelling long-term risk-reward setup.
Strategy: Start small with DCA at current levels, but be patient for deeper dips for larger entries.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.